Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy

@inproceedings{Mkrtichyan2013AntiPD1AS,
  title={Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy},
  author={Mikayel Mkrtichyan and Namju Chong and Rasha Abu Eid and Anu Wallecha and Reshma Singh and John Rothman and Samir N. Khleif},
  booktitle={Journal for immunotherapy of cancer},
  year={2013}
}
BACKGROUND One of the significant tumor immune escape mechanisms and substantial barrier for successful immunotherapy is tumor-mediated inhibition of immune response through cell-to-cell or receptor/ligand interactions. Programmed death receptor-1 (PD-1) interaction with its ligands, PD-L1 and PD-L2, is one of the important strategies that many tumors employ to escape immune surveillance. Upon PD-Ls binding to PD-1, T cell receptor (TCR) signaling is dampened, causing inhibition of… CONTINUE READING
Highly Cited
This paper has 22 citations. REVIEW CITATIONS